^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ERBB3 V104M

    i
    Other names: ERBB3, HER3, LCCS2, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
    Entrez ID:
    2065
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    10ms
    ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments (IASLC-WCLC 2023)
    Molecular profiling of liquid biopsies at baseline identified alterations that could impact on patient outcomes. Our data suggest that the presence of BRAF pathogenic variants may be a good prognostic factor in stage IV NSCLC patients treated with immunotherapy or chemo-immunotherapy, while pathogenic mutations in ERBB3 could be a biomarker of high risk of disease progression. Additional studies analyzing larger cohorts of patients are needed to clarify these hypotheses.
    Clinical • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    BRAF V600E • BRAF mutation • BRAF V600 • BRAF wild-type • ERBB3 mutation • BRAF T599 • ERBB3 V104M
    |
    Oncomine™ Pan-Cancer Cell-Free Assay